Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CDK4/6 Extends Reach Into Early-Stage Breast Cancer

CHICAGO — Adding ribociclib (Kisqali) to adjuvant endocrine therapy significantly improved invasive disease-free survival (iDFS) in patients with early-stage, high-risk breast cancer and hormone receptor (HR)-positive/HER2-negative disease, an interim analysis of a large phase III study found. In the NATALEE trial, which included patients with node-negative disease, the CKD4/6 inhibitor plus endocrine therapy combination resulted […]

Breast Cancer Control Similar With Intermittent, Continuous Endocrine Therapy

Intermittent or continuous extended adjuvant endocrine therapy led to virtually identical long-term survival in hormone receptor (HR)-positive breast cancer, according to an updated analysis of a randomized trial. Disease-free survival (DFS) at 7 years was 81.4% with intermittent extended letrozole and 81.5% with continuous treatment. The results mirrored previously reported 5-year DFS, which also did […]

DBN Health News